130 related articles for article (PubMed ID: 27318623)
1. A genetic score combining CYP450 2C19 and 3A4 genotypes to predict voriconazole plasma exposure?
Gautier-Veyret E; Fonrose X; Stanke-Labesque F
Int J Antimicrob Agents; 2016 Aug; 48(2):221-2. PubMed ID: 27318623
[No Abstract] [Full Text] [Related]
2. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338
[TBL] [Abstract][Full Text] [Related]
3. Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole.
Imamura CK; Furihata K; Okamoto S; Tanigawara Y
J Clin Pharmacol; 2016 Apr; 56(4):408-13. PubMed ID: 26239045
[TBL] [Abstract][Full Text] [Related]
4. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
5. Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes.
Shao B; Ma Y; Li Q; Wang Y; Zhu Z; Zhao H; Sun J; Dong L; Zhu Y; Zhao N; Qin Y
Xenobiotica; 2017 Dec; 47(12):1121-1129. PubMed ID: 27937048
[TBL] [Abstract][Full Text] [Related]
6. CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.
Zhu L; Brüggemann RJ; Uy J; Colbers A; Hruska MW; Chung E; Sims K; Vakkalagadda B; Xu X; van Schaik RH; Burger DM; Bertz RJ
J Clin Pharmacol; 2017 Feb; 57(2):235-246. PubMed ID: 27432796
[TBL] [Abstract][Full Text] [Related]
7. Impact of flavin-containing monooxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients.
Yamada T; Mino Y; Naito T; Kawakami J
J Infect Chemother; 2019 Dec; 25(12):1019-1025. PubMed ID: 31239195
[TBL] [Abstract][Full Text] [Related]
8. Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients.
Fan X; Zhang H; Wen Z; Zheng X; Yang Y; Yang J
Pharmacogenet Genomics; 2022 Jun; 32(4):152-158. PubMed ID: 35081606
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped.
Gautier-Veyret E; Fonrose X; Stanke-Labesque F
Clin Pharmacol Ther; 2017 Aug; 102(2):189. PubMed ID: 28182291
[No Abstract] [Full Text] [Related]
10. Impact of CYP3A4 Genotype on Voriconazole Exposure.
Duflot T; Schrapp A; Bellien J; Lamoureux F
Clin Pharmacol Ther; 2018 Feb; 103(2):185-186. PubMed ID: 28786228
[No Abstract] [Full Text] [Related]
11. Response to "Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4*22 to Metabolism of Voriconazole".
Walsh TJ; Moriyama B; Penzak SR; Klein TE; Caudle KE
Clin Pharmacol Ther; 2018 Feb; 103(2):187. PubMed ID: 28786218
[No Abstract] [Full Text] [Related]
12. High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype.
Bennis Y; Bodeau S; Bouquié R; Deslandes G; Verstuyft C; Gruson B; Andréjak M; Lemaire-Hurtel AS; Chouaki T
Br J Clin Pharmacol; 2015 Oct; 80(4):782-4. PubMed ID: 26138512
[No Abstract] [Full Text] [Related]
13. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies.
Huang FR; Zhou C; Zhang XY; Shen Y; Zhang HW; Wang YQ; Sun LN
Xenobiotica; 2021 Oct; 51(10):1199-1206. PubMed ID: 34402388
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations.
Gautier-Veyret E; Bailly S; Fonrose X; Tonini J; Chevalier S; Thiebaut-Bertrand A; Stanke-Labesque F
Pharmacogenomics; 2017 Aug; 18(12):1119-1123. PubMed ID: 28745547
[TBL] [Abstract][Full Text] [Related]
16. Association of
Zhao T; Shen H; Zhang HL; Feng J; Liu SM; Wang TT; Li HJ; Yu LH
Pharmacogenomics; 2023 Feb; 24(3):141-151. PubMed ID: 36718992
[No Abstract] [Full Text] [Related]
17. Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics.
Hohmann N; Kreuter R; Blank A; Weiss J; Burhenne J; Haefeli WE; Mikus G
Br J Clin Pharmacol; 2017 Sep; 83(9):1954-1965. PubMed ID: 28370390
[TBL] [Abstract][Full Text] [Related]
18. Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?
Zhong X; Tong X; Ju Y; Du X; Li Y
Curr Drug Metab; 2018; 19(14):1152-1158. PubMed ID: 29361899
[TBL] [Abstract][Full Text] [Related]
19. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
[TBL] [Abstract][Full Text] [Related]
20. Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians.
Chawla PK; Nanday SR; Dherai AJ; Soman R; Lokhande RV; Naik PR; Ashavaid TF
Int J Clin Pharm; 2015 Oct; 37(5):925-30. PubMed ID: 26024717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
